The first part of the meeting dealt with animal studies and the use of single agents. Mr 0 M A Wallace (London) noted that, despite the frequency of bladder cancer, the heterogeneity of the bladder cancer population and also of the treatment centres has meant that controlled clinical trials are prolonged and laborious, and stressed that animal models, which have contributed considerably to our understanding of human carcinogenesis, must now be developed for the rapid assessment of agents likely to be effective in the management of human bladder cancer.
The three carcinogens that have proved to be particularly useful in the animal model systems of bladder cancer are N-(4·(5-nitro-2-furyl)·2-thiazolyl)formamide (FANFT), N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) and N-methyl-N-nitrosourea (MNU). FANFT produces the closest resemblance to human bladder cancer, but it is expensive and is a considerable environmental hazard because of its prolonged dietary administration. The other two carcinogens are easier to use and have been most useful in studying carcinogenesis and tumour promotion.
The FANFT-induced bladder cancer in mice has been extensively studied by Soloway & Murphy (1979) , who found that it was difficult to assess the effects of treatment on the primary tumour and use tumours transplanted into the hind leg of a syngeneic animal where they grow at a constant growth rate and are easy to measure. With this system it has been possible to assess the effects of single agentsand combinations of chemotherapeutic agents and radiotherapy on the growth rate of the transplanted tumour.
Tumours can also be implanted into the bladder which has previously been traumatized either chemically or by diathermy burning. The intravesical implanted tumours have been used to study the effect of single-agent intravesical chemotherapy in preventing implantation. Although the results in animal models have been encouraging, further development is necessary before they can become a reliable method of selection of chemotherapeutic agents for clinical trials.
The role of cytotoxic chemotherapy in the treatment and prevention of superficial bladder cancer was discussed by several authors. Mr Peter Riddle (London) advocated the use of intravesical ethoglucid (Epodyl) for those superficial bladder 1 Report of meeting of the Section of Urology with the Section of Oncology, 27 November 1980 0141-0768/81/070547-04/$01.00/0 tumours which cannot be controlled by endoscopic diathermy and resection. Of 64 patients eligible for review, patients fell into three categories: (1) those who became clear and maintained a completely clear bladder on treatment; (2) those who became clear but later regressed; and (3) those who never became clear. On following these cases it became apparent that the first category did very well; the histology of these was all in-situ (Pa), Of the second and third groups, there were increasing numbers of patients with infiltration below the basement membrane, but not into muscle (Pia and PI b), there being a preponderance of PI b in the third group; the majority of these died. Those who survived had usually undergone a radical cystourethrectomy. From this review it seems that, should the patients not respond initially and completely, and/or if their histology is in any way invasive (PIa or Plb), radical surgery should be undertaken.
Mr H R England (London) reported the use of intravesical thiotepa following endoscopic clearance in 45 patients, each with an established pattern of many new GI/G2 tumours at every three-monthly cystoscopy. 30 mg thiotepa in 50 ml saline was instilled for two hours on postoperative days one, three and five (Oravisto 1972) . The dose was reduced to 15mg if there was evidence of bone marrow depression. When a patient responded, one further course was given and thereafter according to individual need to preserve the response. In 32 patients the bladder became clear or the tumour numbers reduced to three or fewer. A marked improvement was commonly noted after the first course and always after the second in these patients. Whilst G I and G2 tumours responded equally well, category PTa responded better than PTI. New tumours were frequently of a lower grade and stage. Eight patients have remained tumour-free without maintenance thiotepa, the longest for four years. In the remaining 24, continuing prophylaxis has been required, but with the passage of time it has usually been possible to reduce the number of instillations and increase the intervals between cystoscopies, suggesting that the therapy has a cumulative effect. Neither systemic nor local toxicity has been a problem. Of the 13 patients who did not respond, 4 died of tumour progression, 3 developed urothelial tumours of the upper tract from which one died, and the remaining 6 have had no change in disease status for up to five years.
Mr Alan Turner (Peterborough) reviewed the literature on the intravesical use of adriamycin (Banks et al. 1977 ,Edsmyr et al. 1979 ,Jacobi et al. 1979 , Niijima 1979 , Pavone-Macaluso & Caramia 1972 , Pavone-Macaluso 1979 , Uyama et al. 1980 and bleomycin (Bracken et al. 1977 , Cunningham et al. 1972 , Smith & McCollum 1976 . Whilst adriamycin has been shown to be active with minimal side effects, bleomycin has proved to be unsuitable for use because of local toxicity. A dose of 50-80 mg adriamycin will produce complete or partial remission of superficial tumours in approximately two-thirds of patients. In reviewing drugs active when used systemically for patients with advanced local or metastatic disease, he commented on the variable response rates reported for adriamycin (Middleman et al. 1971 ,O'Bryan et al. 1973 , Tan et al. 1973 , Turner et al. 1979 , Yagoda 1980 which may be dose related (O'Bryan et al. 1977) , and for bleomycin (Pavone-Macaluso 1976 , Turner et al. 1979 .
Mr Reginald Hall (Newcastle) reviewed methotrexate, an antimetabolite which acts principally during the S phase of cell division by the competitive inhibition of the enzyme dihydrofolate reductase. Its action is as much dependent upon the duration of its administration as upon the concentration of the drug in tissues. It is metabolized in part by the liver but excreted mainly unchanged by the kidneys. In patients with impaired renal function its clearance will be slowed and the risk of toxicity, including myelosuppression, diarrhoea, skin reactions, oral ulceration and renal damage, increased. These effects can be anticipated and prevented by the appropriate use of leucovorin, alkalinization of the urine by the oral administration of sodium bicarbonate and by the regular use of a bacitracin polymyxin nystatin mouthwash. Chemical conjunctivitis may be prevented by the use of leucovorin eye drops. The dose used has ranged from 50 rng orally or intravenously every week to 2 g every three weeks. Methotrexate may be given orally in doses up to 100 mg but should be given intramuscularly or intravenously for amounts up to 200 mg and by intravenous infusion for larger doses. Leucovorin may be required for doses of 100 to 200 mg if given weekly and will always be required if larger quantities are used.
In phase II studies in patients with advanced disease for doses up to 200 mg given intravenously or intramuscularly everyone to four weeks, an overall remission rate of 34% has been obtained. Experience with higher doses is less extensive but an overall remission rate of 6% has been disappointing. No complete remissions have been reported and, in Mr Hall's experience, a very intensive regime of 300 mg/m? every week yielded no significant tumour regression, nor was escalation of the dose to 2 g of apparent benefit. The optimum dose and frequency of administration of methotrexate remain unkown.
Methotrexate has also been used in combination with partial or total cystectomy for the primary treatment of category T3 disease. In 17 patients with T3 tumours, treated by cystectomy plus 2 g methotrexate with appropriate leucovorin every three weeks for six months following partial cystectomy, the two-year survival rate was 100%, all patients remaining tumour free (Soquet 1981) . This work deserves to be repeated.
Oral methotrexate (50 mg weekly) without leucovorin has also been used prophylactically, in a small group of patients with multiple frequentlyrecurring Tl bladder tumours, for eighteen months following initial endoscopic clearance of the bladder. All patients have been cystoscoped at approximately three-monthly intervals and any recurrences have been resected. The effect of methotrexate is being judged by the number and frequency of recurrent tumours developing while taking methotrexate compared with the tumour incidence in the same group of patients during one year prior to treatment. So far, in II out of 16 patients tumour incidence has been reduced.
Mr Mel Robinson (Pontefract) gave a brief report on the current status of two Phase II EORTC (European Organization for Research on the Treatment of Cancer) studies in advanced bladder cancer.
In EORTC Protocol 30797 -a phase II study with vincristine in patients with advanced bladder cancer -the objectives were to measure the tumour response rate and duration of response in patients with advanced bladder cancer receiving cytotoxic chemotherapy with vincristine. The response has been measured in both the primary tumour and marker metastases. One mg/m? vincristine was given intravenously weekly for eight weeks and thereafter every two weeks until tumour progression. Evaluation of the primary tumour and secondary lesions was made at eight weeks and then every twelve weeks. Of the 22 patients so far entered into this study, 4 partial remissions have been reported, 3 in the primary lesion and one in II patients whose indicator lesion has been a distant metastasis. Neurological toxicity has occurred in 7 patients and nausea in two. No haematological toxicity has been seen.
In EORTC protocol 30771, a phase II study of the combination of cis-platinum, cyclophosphamide and adriamycin in patients with advanced bladder cancer, the objectives were to estimate the objective tumour response rate and duration of response following combination chemotherapy with cis-platinum, cyclophosphamide and adriamycin in a limited number of patients with advanced bladder carcinoma. The patients received cis-platinum 40 mg/m", cyclophosphamide 400 mg/m 2 and adriamycin 40 mg/m! intravenously every three weeks. The tumour response has initially been measured three weeks after the first two cycles of treatment. Of the 62 patients entered into this study so far, 44 with measurable metastatic marker lesions are evaluable, with a preliminary response rate of 34%.
In the second session, dealing with combination therapy, Mr Brian Richards (York) reviewed the trial carried out in Yorkshire which compared the survival and disease-free interval in over 100 patients (less than 70 years of age, not previously treated, with adequate renal and cardiac reserve and satisfactory performance status) who had T3, MO transitional cell carcinoma of the bladder. They were divided into two groups, one of which had three weekly injections of adriamycin and 5-fluorouracil and the other group received no additional treatment following a radical course of radiotherapy. The survival curves were almost identical, and there proved to be less than a I in 20 chance of an actual difference of20% in one year's survival being randomly obscured. The chemotherapy regime gave rise to some toxicity and it was felt that adjunctive therapy with these drugs according to this regime could not be recommended in patients with category T3 bladder cancer.
Mr Philip Smith (Leeds) briefly discussed the EORTC studies in which intravesical chemoprophylaxis had been used following complete transurethral resection (TUR) in patients with category TI bladder cancer and the EORTC trial of adjuvant chemotherapy in patients with category T3 cancer. Of the four . EORTC protocols for category TI bladder cancer, the first, comparing thiotepa, VM26 and no additional treatment following complete TUR, had shown thiotepa to be the most effective in preventing recurrence. The second and third studies, comparing intravesical thiotepa, adriamycin and cis-platinum in one, and adriarnycin, ethoglucid (Epodyl) and no additional treatment in the other, continue to recruit patients as does the fourth study designed to evaluate the effect of oral pyridoxine or placebo, a study designed to assess the incidence and importance of abnormal tryptophan metabolites in patients with noninvasive bladder cancer. In the EORTC study of adjuvant 5-fluorouracil and adriamycin, or no additional treatment following radical cystectomy with or without previous 'flash' radiotherapy, for patients with category P3 No-N2 Mo disease, recruitment is slow and no results are available.
Mr A J L Hart (Glasgow) reviewed a pilot study of chemotherapy, using methotrexate 100 mg, 5-fluorouracil 500 mg and cyclophosphamide 500 mg all given intravenously, with folinic acid 15 mg q.i.d. for 48 hours, being started 24 hours after the chemotherapy, in T3 transitional cell bladder tumours at the Western Infirmary, Glasgow. Patients with T3 bladder tumours, as assessed by cystoscopy, biopsy, intravenous urography, ultrasound, bone scan and bimanual examination, were given four pulses of chemotherapy at three weekly intervals prior to a course of radical radiotherapy and subsequent chemotherapy or surgery. Patients were assessed before treatment, after four cycles of chemotherapy and three months after radiotherapy.
Of the' II patients so far evaluable following their initial chemotherapy, there has been one complete response, three partial responses, 5 patients with stable disease and 2 with progression. Evaluation following radiotherapy has so far been possible in 7 patients of whom 5 had a complete response (excluding the patient who showed a complete response to initial chemotherapy), one stable disease and one progression. Of the complete responses, 4 are disease free at 20 months, 16 months, 15 months and 8 months and are receiving intermittent pulses of chemotherapy. One patient with a complete response relapsed at four months, has had a total cystectomy and is alive and disease free at 23 months. The patient who had a complete response to chemotherapy and had no radiotherapy because of protocol violation relapsed at two months and died at seven months. This regime is relatively non-toxic, only one patient having had minor bone marrow depression.
Mr A McGeorge (Glasgow) summarized a prospective randomized trial of chemotherapy for patients with T4 transitional cell carcinoma of the bladder comparing: (I) Methotrexate 100 mg, adriamycin 50 mg and 5-f1uorouracil 500 mg, IV 3-weekly with folinic acid rescue (15 mg 6 hourly x 4 days) (MAF group); (2) Cyclophosphamide 500 mg, adriamycin 50 mg and 5-f1uorouracil 500 mg, IV 3-weekly (CAF group).
Of 14 CAF and 13 MAF patients so far evaluated, the side effects were similar and minimal. Two patients, one in each group, had a partial response at four cycles, but rapidly progressed thereafter and died. One patient in each group at present has stable disease. Ten patients in the CAF group and II patients in the MAF group have died. Three patients in the CAF group, and one in the MAF group have progressed, but are alive at present. Dr R S Pointon (Manchester) evaluated the possibilities of radiotherapy in bladder cancer for control of the primary lesion and the regional lymph nodes. Lymph node involvement is associated with a high incidence of distant metastases. As approximately 70% of radically treated carcinomas of the bladder are free of node involvement, improvement in results would be obtained from a greater success rate in primary control. Radiotherapy remains the principal method of treatment of infiltrating bladder carcinoma, with cystectomy as a salvage procedure. More effective local control with radiotherapy might be obtained by the use of (1) high LET irradiation -fast neutron therapy; (2) combination of X-ray with radiosensitizers; (3) combination of X-ray therapy with cytotoxic agents. Clinical trials are in progress to compare fast neutron therapy with megavoltage X-ray therapy. The use of concurrent methotrexate and X-ray therapy is giving encouraging results in advanced head and neck cancer, and it is proposed to extend this concept to the treatment of bladder cancer. Professor G D Chisholm (Edinburgh) reviewed the place of cystectomy which, despite improvements in surgical techniques and patient care, still carries a mortality of up to 10%. Fifty years or more ago it was close to 50%. In addition, a substantial number of patients die of metastatic bladder cancer within the first few years of the cystectomy. Thus, despite the improved operative technique, the selection of patients (in the hope of cure) has proved to be inadequate. The overall results from cystectomy alone seemed little better than those of radiotherapy alone and it was a reasonable step to try and improve the results using a combination of these treatments. The results of the Wallace & Bloom (1976) T3 trial are well known and indicate that there has been some improvement in the five-year survival rate. Despite this improvement, large numbers of patients still die within one to two years of treatment from metastatic carcinoma of the bladder.
It is probable that the limits of combinations of radiotherapy and surgery have been reached, leaving two possibilities: (I) to pursue a policy of radical radiotherapy followed by salvage cystectomy where necessary; or (2) to include chemotherapy in this combination of treatments.
Chemotherapy for bladder cancer has so far been disappointing but, given some suitable agents, it seems the only modality that might now be incorporated to reduce the pelvic/extra-pelvic recurrences and improve the patient's survival. James's University Hospital. Leeds 
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